Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ClinicalTrials.gov |
Last refreshed on:
|
9 October 2023 |
Main ID: |
NCT01908543 |
Date of registration:
|
23/07/2013 |
Prospective Registration:
|
No |
Primary sponsor: |
|
Public title:
|
Iron Deficiency and Hereditary Haemorrhagic Telangiectasia
|
Scientific title:
|
Iron Deficiency and Hereditary Haemorrhagic Telangiectasia |
Date of first enrolment:
|
July 2013 |
Target sample size:
|
3 |
Recruitment status: |
Terminated |
URL:
|
https://clinicaltrials.gov/ct2/show/NCT01908543 |
Study type:
|
Interventional |
Study design:
|
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
|
Phase:
|
N/A
|
|
Countries of recruitment
|
United Kingdom
| | | | | | | |
Contacts
|
Name:
|
Claire L Shovlin, PhD FRCP |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
Imperial College London |
| | |
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Hereditary haemorrhagic telangiectasia (HHT). Definite diagnosis of HHT by
international criteria.
- No iron tablets or treatment taken on day of assessment
- Ability to provide informed consent.
Exclusion Criteria:
- Inability to provide informed consent
- Intercurrent infection or illness predicted to modify iron absorption.
- Needle phobia.
Age minimum:
18 Years
Age maximum:
80 Years
Gender:
All
|
Health Condition(s) or Problem(s) studied
|
Hereditary Haemorrhagic Telangiectasia
|
Intervention(s)
|
Drug: Ferrous sulphate 200mg oral tablet
|
Primary Outcome(s)
|
Blood iron indices
[Time Frame: 4-5 hours after iron tablet ingestion]
|
Secondary ID(s)
|
CLS 2013/1
|
Source(s) of Monetary Support
|
Please refer to primary and secondary sponsors
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|